Meeting Banner
Abstract #2909

Radiomic features extracted from T2w MRI differentiates KRAS mutational status in rectal cancers: A pilot study

Shanker Raja1,2, Jacob Antunes3, Amrish Selvam3, Anant Madabhushi3, Sharad George1, Mazen Alsagri4, Adnan Hussain2, Abdullah AlDosary2, Musa A Fageeh2, Mohammed AlHarbi2, and Satish E Viswanath3

1Radiology, Baylor College of Medicine, Houston, TX, United States, 2KFMC - Riyadh, Saudi Arabia, 3Biomedical Engineering, Case Western Reserve University, 4KFSH - Qassim

Contemporary management of rectal cancer includes consideration of adjuvant anti EGFR therapy; however, KRAS mutational status profiling is mandatory prior to initiation of this therapy. KRAS mutational status is typically assayed on tissue samples (biopsy/surgical specimens). Radiomic features have demonstrated the ability to quantitatively characterize image phenotypic appearance associated with genotype expression in different tumors. We explored the utility of multi-scale, multi-oriented filter banks to define radiomics signatures that distinguish KRAS mutated vs wildtype tumors on T2W MRI. Initial results indicate that macro-scale radiomic features depict significantly different responses between the 2 genotypic groups.

This abstract and the presentation materials are available to members only; a login is required.

Join Here